Diabetes Mellitus, Type 2
Showing NaN - NaN of 195
NASH - Nonalcoholic Steatohepatitis, Diabetes, Type 2 Trial in Worldwide (IVA337, Placebo, Empagliflozin)
Recruiting
- NASH - Nonalcoholic Steatohepatitis
- Diabetes Mellitus, Type 2
- IVA337
- +2 more
-
Homewood, Alabama
- +40 more
Jan 23, 2023
Diabetes, Type 2 Trial in Worldwide (Semaglutide, Placebo (semaglutide))
Active, not recruiting
- Diabetes Mellitus, Type 2
- Semaglutide
- Placebo (semaglutide)
-
Tuscumbia, Alabama
- +393 more
Jan 17, 2023
Diabetes, Type 2 Trial in Worldwide (Linagliptin, Empagliflozin, Placebo)
Active, not recruiting
- Diabetes Mellitus, Type 2
- Linagliptin
- +2 more
-
Phoenix, Arizona
- +82 more
Aug 23, 2022
Diabetes, Type 2 Trial in Worldwide (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)
Recruiting
- Diabetes Mellitus, Type 2
- Canagliflozin 100 mg
- +2 more
-
Little Rock, Arkansas
- +121 more
Aug 18, 2022
Diabetes, Diabetes, Type 2 Trial in Worldwide (semaglutide, empagliflozin)
Completed
- Diabetes
- Diabetes Mellitus, Type 2
-
Tuscumbia, Alabama
- +105 more
Jul 11, 2022
Diabetes, Diabetes, Type 2 Trial in Worldwide (semaglutide, )
Completed
- Diabetes
- Diabetes Mellitus, Type 2
- semaglutide
- placebo
-
Lancaster, California
- +104 more
Jul 11, 2022
Diabetes, Diabetes, Type 2 Trial in Worldwide (semaglutide, liraglutide, )
Completed
- Diabetes
- Diabetes Mellitus, Type 2
- semaglutide
- +2 more
-
Birmingham, Alabama
- +107 more
Jul 11, 2022
Diabetes, Type 2 Trial in United States (semaglutide, oral glucose-lowering medications (commercially available))
Recruiting
- Diabetes Mellitus, Type 2
- semaglutide
- oral glucose-lowering medications (commercially available)
-
Alhambra, California
- +23 more
Jul 8, 2022
Diabetes, Type 2 Trial in Worldwide (NNC0480-0389, Semaglutide, Placebo (NNC080-0389))
Recruiting
- Diabetes Mellitus, Type 2
- NNC0480-0389
- +3 more
-
Buena Park, California
- +95 more
Mar 31, 2022
Diabetes, Type 2 Trial in Worldwide (Dapagliflozin, Saxagliptin, Placebo)
Active, not recruiting
- Diabetes Mellitus, Type 2
- Dapagliflozin
- +2 more
-
Sacramento, California
- +122 more
Mar 21, 2022
Diabetes, Type 2 Trial in United States (Gan & Lee Insulin Glargine Injection, LantusĀ®)
Completed
- Diabetes Mellitus, Type 2
- Gan & Lee Insulin Glargine Injection
- LantusĀ®
-
Birmingham, Alabama
- +56 more
Mar 23, 2022
Diabetes, Type 2 Trial in Worldwide (BI 456906, Placebo, Semaglutide)
Completed
- Diabetes Mellitus, Type 2
- BI 456906
- +2 more
-
Huntington Park, California
- +79 more
Mar 22, 2022
Diabetes, Type 2, Renal Impairment, Healthy Trial in Miami, Orlando, Saint Paul (PF-06882961 20 mg)
Completed
- Diabetes Mellitus, Type 2
- +2 more
- PF-06882961 20 mg
-
Miami, Florida
- +2 more
Mar 18, 2022
Diabetes, Type 2 Trial in Worldwide (Alogliptin Benzoate, Placebo)
Completed
- Diabetes Mellitus, Type 2
- Alogliptin Benzoate
- Placebo
-
Little Rock, Arkansas
- +54 more
Mar 14, 2022
Diabetes, Diabetes, Type 2 Trial in Worldwide (Insulin degludec, Insulin glargine)
Completed
- Diabetes
- Diabetes Mellitus, Type 2
- Insulin degludec
- Insulin glargine
-
Anniston, Alabama
- +228 more
Jan 6, 2022
Diabetes, Diabetes, Type 2 Trial in Worldwide (Faster-acting insulin aspart, Insulin aspart, Insulin degludec)
Completed
- Diabetes
- Diabetes Mellitus, Type 2
- Faster-acting insulin aspart
- +3 more
-
Concord, California
- +166 more
Jan 6, 2022
Diabetes, Diabetes, Type 2 Trial in Worldwide (liraglutide, , metformin)
Completed
- Diabetes
- Diabetes Mellitus, Type 2
- liraglutide
- +2 more
-
Birmingham, Alabama
- +184 more
Jul 1, 2021
Diabetes, Type 2 Trial in Worldwide (LY2944876, Exenatide extended-release, Placebo)
Diabetes, Diabetes, Type 2 Trial in Worldwide (semaglutide, oral )
Completed
- Diabetes
- Diabetes Mellitus, Type 2
- semaglutide
- oral placebo
-
Tucson, Arizona
- +102 more
Jan 14, 2021
Diabetes, Type 2 Trial in United Kingdom, United States (BYM338 10 mg/kg, Placebo)
Completed
- Diabetes Mellitus, Type 2
- BYM338 10 mg/kg
- Placebo
-
Anaheim, California
- +8 more
Dec 9, 2020